Should Organizations Be Paid for Quality Performance?

The prompt asks for a position and the reason for it, so lead with the position rather than circling. But notice that the honest answer is conditional, and saying so is a stronger move than picking a side and defending it flatly. Paying for quality is obviously preferable to paying for volume, which rewards doing more regardless of benefit. The difficulty is entirely in the measure. A programme that pays on process measures — was the antibiotic given on time, was the assessment completed — buys compliance with a documented step and gets it, but the step may not be the thing that changes outcomes. A programme that pays on outcome measures buys the appearance of better outcomes, and if risk adjustment is imperfect the cheapest route to that appearance is to avoid the sickest patients, which is a documented effect rather than a theoretical worry.

Bring evidence rather than intuition. Evaluations of pay-for-performance across US and international programmes have found effects that are consistently modest, sometimes null, and largest where the baseline was worst — which is itself informative, since it suggests these schemes work as a floor rather than as a ceiling. Then name the design features that separate a defensible scheme from a harmful one: risk adjustment that is actually adequate, measures that clinicians accept as meaningful, rewards for improvement as well as for attainment so that safety-net providers are not structurally excluded, and a payment large enough to matter but not so large that gaming becomes rational. Close on the position you actually hold, applied to your own setting, and mention the unintended consequence you would watch for — that is the sentence that shows you thought past the question. Name the measure you would refuse to be paid on, and say why you would refuse it.